MEDICAL ONCOLOGY

CLOSED TO RECRUITMENT — AUSTRALIA

Abbrev. Title

MX39795 CUPISCO

Protocol Title

A Phase II, Randomized, Active-Controlled, Multi-Center Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Guided by Genomic Profiling Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Who Have Received Three Cycles of Platinum Doublet Chemotherapy

ONT 380-206 HER2CLIMB Phase 2 Randomized, Double-Blinded, Controlled Study of ONT-380 Vs. Placebo in Combination with Capecitabine and Trastuzumab in Patients with Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma

ORBIT-M

Optimized Response Biome for Immunotherapy Treatment

R2810-ONC-1540

A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma

R2810-ONC-1540

A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death–1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma

R2810-ONC-1540

A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death–1 (PD-1), in Patients with Advanced Cutaneous Squamous Cell Carcinoma

SHR-1701-001 AUS

A Phase 1, Open-Label, Multi-Center, Non-Randomized, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of SHR-1701 in Subjects with Advanced Solid Tumours

SHR3680-002

A Phase 1 Trial of SHR3680 with or Without SHR3162 in Subjects with Metastatic Castration-Resistant Prostate Cancer

Statins-Lipidomics

Statins in Metastatic Castration-Resistant Prostate Cancer: Multi-Centre, Open Label Trial of Simvastatin in Addition to Docetaxel Chemotherapy for Metastatic CastrationResistant Prostate Cancer

TRIO033

NATALEE

A Phase 3 Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib with Endocrine Therapy as an Adjuvant Treatment in Patients with Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl with Ribociclib